PLRZ Polyrizon Ltd.
$8.61▲ +0.35%
Healthcare
Other
Volume 3.2K
Avg Volume (10D) 27.3K
Key Metrics & Fundamentals
Market Cap
$20.91M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.88 - 18.20
% vs 50 MA
-18.50%
% vs 200 MA
-32.09%
RSI-14
37.6
MACD Histogram
-0.0400
Beta (1Y vs SPY)
0.98
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
GlobeNewswire · Oct 27, 2026 8:16 AM ET
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
GlobeNewswire · Oct 5, 2026 7:32 AM ET
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
GlobeNewswire · Sep 22, 2026 8:33 AM ET
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
GlobeNewswire · Sep 4, 2026 11:58 AM ET
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
GlobeNewswire · Sep 3, 2026 8:50 AM ET
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
GlobeNewswire · Sep 2, 2026 7:32 AM ET
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
GlobeNewswire · Aug 20, 2026 9:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.